» Articles » PMID: 9513709

Interactions Between the Oestrogen and Insulin-like Growth Factor Signalling Pathways in the Control of Breast Epithelial Cell Proliferation

Overview
Specialty Biochemistry
Date 1998 Mar 26
PMID 9513709
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing evidence for interactions between steroid and growth factor signalling pathways. Oestrogens modulate the responsiveness of breast epithelial cells to insulin-like growth factors (IGFs), and this may be the mechanism by which oestrogens modulate cell proliferation. Oestrogens appear to act at several points in the IGF signal transduction pathway. Despite earlier studies suggesting that breast epithelial cells do not synthesize IGF-I, we have shown by PCR that IGF-I is expressed and that its expression is regulated by oestrogen. IGF-II is expressed at markedly higher levels than IGF-I and is also regulated by oestrogen, consistent with it being an oestrogen-regulated autocrine growth factor. Oestrogens regulate the expression of IGF binding proteins and the type I IGF receptor. The biological significance of oestrogen regulation of IGF binding protein expression is not clear. Experiments in which the type I IGF receptor has been constitutively overexpressed have suggested that oestrogen regulation of the receptor is not involved in mediating the effects of oestrogen on cell proliferation. Recent studies have started to assess the effects of oestrogen on the expression of components of the IGF signal transduction pathway, and have shown that the expression of insulin receptor substrate-1, the principal substrate for the tyrosine kinase of the type I IGF receptor, is regulated by oestradiol.

Citing Articles

Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.

May F Cancer Manag Res. 2014; 6:225-52.

PMID: 24904222 PMC: 4041375. DOI: 10.2147/CMAR.S35024.


A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.

Westley R, May F Int J Endocrinol. 2013; 2013:632461.

PMID: 23983688 PMC: 3747439. DOI: 10.1155/2013/632461.


Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.

Davison Z, de Blacquiere G, Westley B, May F Neoplasia. 2011; 13(6):504-15.

PMID: 21677874 PMC: 3114244. DOI: 10.1593/neo.101590.


Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Nicholson R, Gee J Br J Cancer. 2000; 82(3):501-13.

PMID: 10682656 PMC: 2363333. DOI: 10.1054/bjoc.1999.0954.


Antiestrogens--tamoxifen, SERMs and beyond.

Dhingra K Invest New Drugs. 2000; 17(3):285-311.

PMID: 10665480 DOI: 10.1023/a:1006348907994.